Skip to main content
VVT MED INC. logo

VVT MED INC. — Investor Relations & Filings

Ticker · VVTM ISIN · CA91841T1084 TSXV Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CA Canada
Listing TSXV VVTM

About VVT MED INC.

https://www.vvtmed.com/

VVT MED INC. develops, manufactures, and commercializes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of varicose veins and chronic venous disorders. The company's technology centers on the ScleroSafe Platform, a patented delivery system for Endovenous Chemical Ablation (ECA). ScleroSafe is designed to simplify procedures, shorten treatment times, and minimize patient recovery compared to traditional surgical and ablation methods. Products like ScleroSafe and V-Block, which treats severely dilated Great Saphenous Vein conditions, offer enhanced safety and efficacy. The platform holds regulatory clearances including FDA 510(k) and CE approval.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a news release updating on a management cease trade order issued by the British Columbia Securities Commission under NP 12-203 due to continuous disclosure defaults. It does not contain actual financial statements or MD&A, nor is it the report itself, but rather a regulatory compliance update and ongoing disclosure notice. It falls under general regulatory announcements/fallback filings.
2026-05-15 English
News release - English.pdf
Regulatory Filings
2026-05-02 English
Report of Distributions outside Canada (Form 72-503F).pdf
Capital/Financing Update Classification · 80% confidence The document is a Canadian National Instrument 72-503F “Report of Distributions Outside Canada,” detailing an exempt distribution of securities (number of units/shares, prices, distribution dates, dealers, and certification). It is a regulatory compliance form covering a fundraising event and capital structure change rather than a periodic report or earnings release. This aligns with the “Capital/Financing Update” category (CAP).
2026-04-27 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2026-04-27 English
News release - English.pdf
Share Issue/Capital Change Classification · 82% confidence The document is a detailed offering prospectus (“document d’offre”) in French for a private placement of 12,988,000 common shares (with an over-allotment option) by Astra Exploration Inc. under the Canadian prospectus exemption regime (Règlement 45-106). It sets out pricing, use of proceeds, closing date, and legal disclaimers – i.e., a share issue/fundraising transaction. This clearly falls under “Share Issue/Capital Change” (SHA).
2026-04-22 French
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a full offering memorandum (“document d’offre”) for a private placement of 12,988,000 common shares (with an over-allotment option) by Astra Exploration Inc. under Regulation 45-106. It details the fundraising structure, price, proceeds, use of funds, closing date, and legal disclaimers related to the issuance of new equity. This is clearly a capital raising/financing document rather than a general regulatory notice or annual/interim report. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-22 French

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.